Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain ...

The trial results are critical, as it brings Eli Lilly’s pill one step closer to becoming a new, needle-free alternative for ...

Eli Lilly and Company (NYSE:LLY), with a market capitalization of $771 billion, stands as a prominent player in the pharmaceuticals industry. The company has been making significant strides in the ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are now.

Novo Nordisk said Wednesday it will sell Wegovy for $499 a month in cash to patients who can’t get the blockbuster weight-loss drug through insurance, a bid to reach consumers who can’t afford ...

Patients, doctors and investors will soon learn a lot more about a new, more convenient treatment that could shake up the booming weight loss drug market. Analysts expect the pill to be as ...